Climb Bio reports Q3 2026 results, dosing underway in IgAN Phase 2 trial

Climb Bio, Inc. reported financial results for the third quarter ended September 30, 2026, on November 5, 2026, alongside business updates across its two clinical programs.

The company said it initiated dosing in NAVIGATE-2, a Phase 2 trial in IgA nephropathy, with enrollment ongoing; the randomized, open-label study evaluates an 800 mg loading dose of CLYM116 followed by 400 mg every 8 weeks or every 12 weeks, intended to support advancement of a Q12W regimen into Phase 3.¹ Climb said it anticipates initial NAVIGATE-2 data in the first half of 2027, and initiation of a global Phase 3 trial in 2027, pending regulatory feedback.¹

Supporting that dosing plan, the company reported encouraging Phase 1 data supporting the Q12W dosing interval at the September R&D Spotlight Event and at American Society of Nephrology Kidney Week 2026, from complementary Phase 1 trials in Australia and China that enrolled 46 and 42 participants, respectively.¹ Across the two studies, pharmacokinetics were linear with no target-mediated drug disposition observed, and more than 90% free APRIL suppression was sustained through 12 weeks following a single subcutaneous dose of at least 480 mg, while a single 800 mg dose produced about a 70% reduction in Gd-IgA1 and about a 60% reduction in IgA at 12 weeks.¹

On budoprutug, the company presented initial PrisMN Phase 2 pMN data showing that at Week 12, the 200 mg cohort demonstrated B-cell depletion, reductions in PLA2R antibody levels, and immunologic remission.¹ In SLE, as of an October 7, 2026 data cutoff, 17 participants had enrolled across 10 mg, 30 mg and 100 mg single-dose cohorts, with B-cell depletion deepening with dose and reaching a mean 84% reduction at Week 12 in the 100 mg cohort.¹ Additional ITP data are expected at ASH in December 2026, and additional pMN and SLE data are expected in 2027.

Financially, cash, cash equivalents and marketable securities were $227.6 million as of September 30, 2026, which the company expects to fund operations into the second half of 2028.¹